卵泡刺激素δ刺激卵巢后获卵数与一年累积活产率的关系:四项随机对照试验的汇总分析
该汇总分析纳入四项随机对照试验的1746例患者,评估卵泡刺激素δ刺激后获卵数与新鲜及后续冻融周期累积活产率(CLBR)的关系。结果显示CLBR随获卵数增加而升高,在21-25个卵子时达到平台;获卵数>15个时CLBR超过60%,>20个时超过70%。年龄≥38岁患者从15个卵子起预测CLBR持续增加,而<38岁患者无同等获益。
要点
- CLBR随获卵数增加而升高,在21-25个卵子时进入平台期。
- 获卵数>15个时CLBR超过60%,>20个时超过70%。
- 年龄≥38岁患者从15个卵子起预测CLBR持续增加,<38岁患者无同等获益。
核心结论
- 在卵泡刺激素δ刺激的新鲜周期及后续冻融周期中,CLBR随获卵数增加而升高,至21-25个卵子时开始进入平台。
- 年龄较大(≥38岁)患者从20个卵子起CLBR增加明显,而年轻患者无同等获益。
研究设计与样本
- 汇总分析,纳入来自四项随机对照试验的1746例患者;试验来自Ferring Pharmaceuticals数据库截至2023年6月可用的临床试验。
- 纳入标准为使用卵泡刺激素δ进行卵巢刺激且至少获得一个卵子的患者;排除卵泡刺激素δ剂量反应试验及重复卵巢刺激周期试验。
- 患者为18-42岁女性,接受首次或第二次IVF/ICSI周期,采用GnRH拮抗剂/激动剂方案。
- CLBR计算为至少一次活产的患者数除以纳入分析的全部患者数。
主要发现
- 共1746例患者纳入分析,平均年龄33.8岁(范围21-42岁),AMH中位数17.0 pmol/l(范围0.3-164.2 pmol/l)。
- 1645例(94.2%)采用GnRH拮抗剂方案,101例(5.8%)采用GnRH激动剂方案;1541例(88.3%)使用hCG触发,205例(11.7%)使用GnRH激动剂触发。
- 740例(42.4%)启动了冻融周期(最多六个);研究人群共进行2948个周期:1746个新鲜周期和1202个冻融周期。
- 平均获卵数12.4个(范围1-72),新鲜周期活产率29.1%,CLBR为51.4%。
- CLBR随获卵数增加而升高,至21-25个卵子时进入平台;获卵数>15个时CLBR超过60%,>20个时超过70%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 分析中获卵数≥20个的患者数量有限(249例,14.3%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What number of oocytes retrieved is associated with the highest cumulative live birth rates (CLBRs) in the fresh and subsequent frozen cycles following ovarian stimulation with follitropin delta? SUMMARY ANSWER: The CLBR increased with the number of oocytes retrieved, plateauing at 21-25 oocytes. WHAT IS KNOWN ALREADY: Live birth rate (LBR) per fresh cycle is the conventionally reported outcome of IVF; however, the marked increase in cryopreserved cycles in recent years suggests that the CLBR has emerged as a more relevant outcome. In the fresh cycle, the number of oocytes retrieved is regarded as a prognostic factor for LBR, and a similar association has been shown for CLBR. STUDY DESIGN, SIZE, DURATION: Pooled analysis including 1746 patients from four randomized controlled trials. Trials were identified from clinical trials available in the Ferring Pharmaceuticals database up to June 2023. Selected trials used follitropin delta for ovarian stimulation and collected outcome data from both fresh and frozen cycles. Follitropin delta dose-response trials, as well as trials investigating follitropin delta in repeated ovarian stimulation cycles, were excluded. Patients included in the analysis underwent ovarian stimulation with follitropin delta and had at least one oocyte retrieved. The outcome of CLBR in the fresh and subsequent frozen cycles was evaluated in relation to the number of oocytes retrieved. CLBR was calculated as the number of patients with at least one live birth divided by the number of all patients included in the analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: Trial participants were women, 18-42 years of age, who were undergoing their first or second IVF/ICSI cycle in a GnRH antagonist/agonist protocol. Triggering was performed with hCG or GnRH agonist, and insemination was performed by IVF or ICSI. Single or double blastocyst transfer was performed on Day 5 in the fresh cycle, and all viable surplus blastocysts were cryopreserved on Day 5 or Day 6. All pregnancies from the fresh cycle and frozen cycles initiated within 1 year after the start of stimulation were followed until birth. The association between the number of oocytes retrieved and CLBR was assessed using a logistic regression analysis with fractional polynomials to obtain predicted CLBR. Subgroup analyses were performed based on age, anti-Müllerian hormone (AMH), and number of oocytes retrieved. MAIN RESULTS AND THE ROLE OF CHANCE: Overall, 15 trials with follitropin delta were identified in the database. Of those, 11 trials were not eligible, and the remaining 4 trials were included. In total, 1746 patients were included in the analysis. The mean age was 33.8 years (range 21-42 years), and the median AMH level was 17.0 pmol/l (range 0.3-164.2 pmol/l). The vast majority of patients (1645 patients, 94.2%) were treated with a GnRH antagonist protocol, while 101 patients (5.8%) were treated with a GnRH agonist protocol. Overall, 1541 patients (88.3%) received hCG triggering, and 205 patients (11.7%) received GnRH agonist triggering. Frozen cycles (maximum of six) were initiated by 740 patients (42.4%). The study population underwent a total of 2948 cycles: 1746 fresh cycles (referring to ovarian stimulation cycles, with or without transfer) and 1202 frozen cycles (initiated cycles, with or without transfer). The mean number of oocytes retrieved was 12.4 (range 1-72), the fresh cycle LBR was 29.1%, and the CLBR was 51.4%. The CLBR increased with the number of oocytes retrieved up to a plateau starting at 21-25 oocytes. The CLBR reached above 60% at >15 oocytes and above 70% at >20 oocytes. The CLBR decreased with increasing age (57.1%, 51.6%, and 35.8% at <35, 35-37, and ≥38 years), while it was similar for AMH <15 and ≥15 pmol/l (52.0% and 50.9%, respectively). A continued increase in predicted CLBR from 15 oocytes retrieved was observed in older patients (≥38 years); from 41.3% to 53.4% to 58.7% at 15-19, 20-24, and ≥25 oocytes. No equivalent benefit was observed in younger patients (<38 years), where corresponding rates were 72.5%, 68.0%, and 78.8% in patients <35 years and 70.3%, 73.1%, and 71.5% in patients 35-37 years. The fresh cycle LBR decreased beyond 14 oocytes, while the CLBR continued to increase by the number of oocytes retrieved. LIMITATIONS, REASONS FOR CAUTION: A limited number of patients included in the analysis had ≥20 oocytes retrieved (249 patients, 14.3%). WIDER IMPLICATIONS OF THE FINDINGS: This analysis suggests an increase in CLBR with the number of oocytes retrieved up to a plateau starting at 21-25 oocytes following ovarian stimulation cycles with follitropin delta and subsequent frozen cycles. An increase in CLBR from 20 oocytes was evident in older but not in younger patients. STUDY FUNDING/COMPETING INTEREST(S): The study was funded by Ferring Pharmaceuticals A/S, Copenhagen, Denmark. S.S.-R. has received research funding from Organon/MSD, Theramex, and Gedeon-Richter, consulting fees from Organon/MSD, Ferring Pharmaceuticals, Merck Serono, and IBSA, payment or honoraria from Organon/MSD, Besins and Gedeon-Richter, support for attending meetings from Gedeon-Richter and Besins, is an advisory board member for TTRANSPORT and Deputy of the ESHRE SQART SIG, and owns stocks of IVI Lisboa, Clinica de Reprodução assistida Lda. A.P. has received grants from Cryos, grants and payments from Gedeon Richter, Ferring Pharmaceuticals and Merck A/S, payments from Organon, consulting fees from IBSA, Ferring Pharmaceuticals, Gedeon Richter, Cryos, and Merck A/S, and travel support from Gedeon Richter. N.S.M. has received speaker and consultancy fees from Ferring Pharmaceuticals, IBSA, Merck, Freya, and Gedeon Richter, and is a shareholder in Verso Biosense. K.M. has been a scientific advisor for Calla Lily Clinical Care, Evvy, and AutoIVF. R.L., A.F., K.M., and I.E.J. are employees of Ferring Pharmaceuticals. REGISTRATION NUMBER: N/A.
引用
- Lobo R, Santos-Ribeiro S, Falahati A, et al. One-year cumulative live birth rate associated with the number of oocytes in ovarian stimulation with follitropin delta: a pooled analysis of four randomized controlled trials. Hum Reprod. 2025. PMID: 40505136. doi:10.1093/humrep/deaf111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。